{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:21:49Z","timestamp":1777594909994,"version":"3.51.4"},"reference-count":38,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"3","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["J Clin Oncol"],"published-print":{"date-parts":[[2026,1,20]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Low-grade serous carcinoma (LGSOC) of the ovary, fallopian tube, or peritoneum is a hormonally driven, relatively chemoresistant malignancy with limited treatment options in the recurrent setting. Given frequent estrogen receptor (ER) expression and dysregulation of the cyclin-dependent kinases 4 and 6 (CDK4\/6)\u2013p16\u2013Rb pathway, features shared with hormone receptor\u2013positive breast cancer, dual endocrine, and CDK4\/6 inhibition is a biologically rational strategy. This phase II trial evaluated ribociclib plus letrozole in recurrent LGSOC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>This open-label, single-arm, multicenter phase II study enrolled women with measurable, recurrent LGSOC. Patients received ribociclib (600 mg orally, once daily, days 1-21 of a 28-day cycle) and letrozole (2.5 mg orally, once daily). The primary end point was investigator-assessed objective response rate (ORR) per RECIST 1.1. Secondary end points included clinical benefit rate (CBR), progression-free survival (PFS), overall survival (OS), and safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>Of 74 patients screened, 51 were enrolled and 49 treated. The confirmed ORR was 30.6% (90% CI, 19.9 to 43.2), including one complete and 14 partial responses. Among responders, the median duration of response was 21.2 months. The CBR was 84% (90% CI, 72.5 to 91.6). The median PFS was 14.5 months (90% CI, 10.1 to 28.8), and the median OS was 44.5 months (90% CI, 31.8 to not reached). The most common grade \u22653 adverse event (AE) was neutropenia (47%), managed with dose modifications. Three grade 5 events (6%) occurred but were unrelated to treatment. Treatment discontinuation because of AEs occurred in 4%. No dose-limiting toxicities were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>Ribociclib plus letrozole met the primary end point, achieving meaningful response rates and durable disease control in recurrent LGSOC. The safety profile was consistent with prior CDK4\/6 inhibitor studies. This combination represents a therapeutic option in this rare and genomically distinct subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco-25-01348","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T20:59:17Z","timestamp":1765573157000},"page":"153-163","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":5,"title":["Phase II Trial of Ribociclib Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube, or Peritoneum: A GOG Partners Trial (GOG 3026)"],"prefix":"10.1200","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7241-3096","authenticated-orcid":true,"given":"Brian M.","family":"Slomovitz","sequence":"first","affiliation":[{"name":"Mount Sinai Medical Center, Miami, FL"}]},{"given":"S. John","family":"Weroha","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center, Buffalo, NY"}]},{"given":"Hye Sook","family":"Chon","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3103-3043","authenticated-orcid":true,"given":"Vivek","family":"Podder","sequence":"additional","affiliation":[{"name":"Mount Sinai Medical Center, Miami, FL"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3567-3494","authenticated-orcid":true,"given":"Mary Tilley","family":"Jenkins Vogel","sequence":"additional","affiliation":[{"name":"Endeavor Health, NorthShore University Health System, Evanston, IL"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9225-6913","authenticated-orcid":true,"given":"Floor","family":"Backes","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}]},{"given":"Eric D.","family":"Thomas","sequence":"additional","affiliation":[{"name":"Oklahoma Cancer Specialists and Research Institute, LLC (OCSRI), Tulsa, OK"}]},{"given":"Lee-May","family":"Chen","sequence":"additional","affiliation":[{"name":"University of California, San Francisco (UCSF), San Francisco, CA"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1336-096X","authenticated-orcid":true,"given":"Meaghan Elizabeth","family":"Tenney","sequence":"additional","affiliation":[{"name":"Northside Hospital, Atlanta, GA"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-0156","authenticated-orcid":true,"given":"Shannon N.","family":"Westin","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}]},{"given":"Merry Jennifer","family":"Markham","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine, UF Health Cancer Center, Gainesville, FL"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8215-5887","authenticated-orcid":true,"given":"David S.","family":"Miller","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, TX"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6708-7380","authenticated-orcid":true,"given":"Mitchell I.","family":"Edelson","sequence":"additional","affiliation":[{"name":"Jefferson Abington Hospital, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[{"name":"University of New Mexico Comprehensive Cancer Center, Albuquerque, NM"}]},{"given":"Michael J.","family":"Callahan","sequence":"additional","affiliation":[{"name":"St Vincent Health, Inc d\/b\/a Ascension St Vincent, Indianapolis, IN"}]},{"given":"Laura L.","family":"Holman","sequence":"additional","affiliation":[{"name":"Stephenson Cancer Center, University of Oklahoma Health Sciences Center (OUHSC), Oklahoma City, OK"}]},{"given":"J. Rebecca","family":"Liu","sequence":"additional","affiliation":[{"name":"Trinity Health-St. Joseph Mercy Hospital, Ypsilanti, MI"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8179-6079","authenticated-orcid":true,"given":"Eleonora","family":"Teplinsky","sequence":"additional","affiliation":[{"name":"Valley Health System, Paramus, NJ"}]},{"given":"Aparna","family":"Kamat","sequence":"additional","affiliation":[{"name":"Houston Methodist Sugar Land Hospital, Houston, TX"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6752-8959","authenticated-orcid":true,"given":"Michael","family":"Guy","sequence":"additional","affiliation":[{"name":"Miami Valley Hospital South, Centerville, OH"}]},{"given":"Jing-Yi","family":"Chern","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center, Tampa, FL"}]},{"given":"Jayanthi","family":"Lea","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas, TX"}]},{"given":"Martina","family":"Murphy","sequence":"additional","affiliation":[{"name":"University of Florida College of Medicine, UF Health Cancer Center, Gainesville, FL"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9668-6072","authenticated-orcid":true,"given":"Grace M.","family":"Choong","sequence":"additional","affiliation":[{"name":"Mayo Clinic, Rochester, MN"}]},{"given":"Elena D.","family":"Moore","sequence":"additional","affiliation":[{"name":"Endeavor Health, NorthShore University Health System, Evanston, IL"}]},{"given":"Edwin A.","family":"Alvarez","sequence":"additional","affiliation":[{"name":"University of California, San Francisco (UCSF), San Francisco, CA"}]},{"given":"William H.","family":"Rodgers","sequence":"additional","affiliation":[{"name":"New York Presbyterian Queens, Flushing, NY"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2828-0177","authenticated-orcid":true,"given":"David M.","family":"O'Malley","sequence":"additional","affiliation":[{"name":"The Ohio State University, James Cancer Center, Columbus, OH"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6204-0962","authenticated-orcid":true,"given":"Larry J.","family":"Copeland","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center, Columbus, OH"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4584-8908","authenticated-orcid":true,"given":"Thomas J.","family":"Herzog","sequence":"additional","affiliation":[{"name":"University of Cincinnati, University of Cincinnati Cancer Center, Cincinnati, OH"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9343-8754","authenticated-orcid":true,"given":"Robert L.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Texas Oncology, US Oncology Network, The Woodlands, TX"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9712-2140","authenticated-orcid":true,"given":"David M.","family":"Gershenson","sequence":"additional","affiliation":[{"name":"University of Texas MD Anderson Cancer Center, Houston, TX"}]}],"member":"233","reference":[{"key":"e_1_3_11_2_2","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2018.29.e15"},{"key":"e_1_3_11_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000227787.24587.d1"},{"key":"e_1_3_11_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01164"},{"key":"e_1_3_11_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-008-0078-8"},{"key":"e_1_3_11_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.0873"},{"key":"e_1_3_11_7_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004898"},{"key":"e_1_3_11_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004610"},{"key":"e_1_3_11_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70253-5"},{"key":"e_1_3_11_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.02.037"},{"key":"e_1_3_11_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.06.011"},{"key":"e_1_3_11_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02175-9"},{"key":"e_1_3_11_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00112"},{"key":"e_1_3_11_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2019.12.033"},{"key":"e_1_3_11_15_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0816"},{"key":"e_1_3_11_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_3_11_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113480"},{"key":"e_1_3_11_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30786-7"},{"key":"e_1_3_11_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26618"},{"key":"e_1_3_11_20_2","first-page":"18","volume-title":"WHO Classification of Tumours of Female Reproductive Organs","author":"Kurman RJ","year":"2014","unstructured":"Kurman RJ, Carcangiu ML, Herrington CS, et al (eds): WHO Classification of Tumours of Female Reproductive Organs. Lyon, France, International Agency for Research on Cancer (IARC), 2014, p 18"},{"key":"e_1_3_11_21_2","volume-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","author":"U.S. Department of Health and Human Services","year":"2017","unstructured":"U.S. Department of Health and Human Services: Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. National Institutes of Health. 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf"},{"key":"e_1_3_11_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70572-7"},{"key":"e_1_3_11_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19981030)17:20<2301::AID-SIM927>3.0.CO;2-X"},{"key":"e_1_3_11_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2004.12.007"},{"key":"e_1_3_11_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911149"},{"key":"e_1_3_11_26_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903765"},{"key":"e_1_3_11_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70253-5"},{"key":"e_1_3_11_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/cjp2.109"},{"key":"e_1_3_11_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2016.01.022"},{"key":"e_1_3_11_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2009.03.001"},{"key":"e_1_3_11_31_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13123035"},{"key":"e_1_3_11_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2020-000926"},{"key":"e_1_3_11_33_2","article-title":"FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer","author":"FDA","year":"2025","unstructured":"FDA: FDA grants accelerated approval to the combination of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer. News release, 2025. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-combination-avutometinib-and-defactinib-kras-mutated-recurrent-low","journal-title":"News release"},{"key":"e_1_3_11_34_2","first-page":"155","article-title":"Prognostic and predictive factors in breast cancer by immunohistochemical analysis","volume":"11","author":"Allred DC","year":"1998","unstructured":"Allred DC, Harvey JM, Berardo M, et al: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11:155-168, 1998","journal-title":"Mod Pathol"},{"key":"e_1_3_11_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00288-2"},{"key":"e_1_3_11_36_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0052"},{"key":"e_1_3_11_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2023.06.222"},{"key":"e_1_3_11_38_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0035"},{"key":"e_1_3_11_39_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2022.40.16_suppl.5522"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO-25-01348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T22:59:55Z","timestamp":1768431595000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO-25-01348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,20]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,1,20]]}},"alternative-id":["10.1200\/JCO-25-01348"],"URL":"https:\/\/doi.org\/10.1200\/jco-25-01348","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,20]]},"assertion":[{"value":"2025-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}